Sopherion Therapeutics

About Sopherion Therapeutics

Sopherion Therapeutics, LLC was a privately-held biopharmaceutical company established in 2000 with a focus on addressing unmet needs in cancer treatment. The company's primary mission was the acquisition, discovery, development, and commercialization of anti-cancer therapies, particularly for patients with advanced, metastatic disease. Headquartered in Princeton, New Jersey, Sopherion also maintained preclinical research and development operations in New Haven, Connecticut, and an operating subsidiary in Toronto, Canada.

The company's business model centered on in-licensing and developing promising anti-cancer agents. A significant part of its strategy involved its lead product candidate, Myocet™, a liposomal formulation of the chemotherapy drug doxorubicin. This formulation was engineered to reduce the risk of cardiotoxicity, a common side effect of doxorubicin, while maintaining its anti-tumor effectiveness. Sopherion secured the North American commercialization rights for Myocet through a licensing agreement with Zeneus Pharma Ltd. in 2004. The company's pipeline was also supported by its Minicell Peptide Display screening technologies, aimed at identifying new therapies for cancer.

Sopherion's operations were financed through substantial venture capital backing. Over its lifespan, the company raised a total of $128 million across several funding rounds. Key financing events included a $26 million Series A round in March 2003, a $47 million Series B round in September 2004, and a pivotal $55 million Series C financing in February 2009. This later funding, led by Zoticon Bioventures, was critical for advancing Myocet through a global Phase III clinical trial. The trial investigated Myocet in combination with other drugs for the first-line treatment of metastatic breast cancer. A diverse group of institutional investors supported the company, including TL Ventures, New Leaf Venture Partners, ProQuest Investments, and Canaan Partners. The company was reported to be out of business as of October 2018.